Trial reportThe American journal on addictions
Early outcomes following low dose naltrexone enhancement of opioid detoxification.
Trial report in The American journal on addictions. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Diversity inclusion in United States opioid pharmacological treatment trials: A systematic review.Experimental and clinical psychopharmacology · 2021Pooled it
- Pharmacological therapies for management of opium withdrawal.The Cochrane database of systematic reviews · 2018Pooled it
- Opioid antagonists with minimal sedation for opioid withdrawal.The Cochrane database of systematic reviews · 2017Pooled it
- Rapid Initiation of Injection Naltrexone for Opioid Use Disorder: A Stepped-Wedge Cluster Randomized Clinical Trial.JAMA network open · 2024Trial
- Simultaneous Determination of Levo-tetrahydropalmatine and Naltrexone in Rat Plasma by LC-MS/MS and its Application in a Pharmacokinetic Study.Current pharmaceutical biotechnology · 2024Article
- The Utilization of Low Dose Naltrexone for Chronic Pain.CNS drugs · 2023Article
- Opiate Antagonists for Chronic Pain: A Review on the Benefits of Low-Dose Naltrexone in Arthritis versus Non-Arthritic Diseases.Biomedicines · 2023Review
- Negative affect-associated drug refusal self-efficacy, illicit opioid use, and medication use following short-term inpatient opioid withdrawal management.Journal of substance abuse treatment · 2021Article
- Very low dose naltrexone in opioid detoxification: a double-blind, randomized clinical trial of efficacy and safety.Toxicological research · 2020Article
- Potential uses of naltrexone in emergency department patients with opioid use disorder.Clinical toxicology (Philadelphia, Pa.) · 2019Review
- Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization.Medical sciences (Basel, Switzerland) · 2018Review
- Antagonists in the medical management of opioid use disorders: Historical and existing treatment strategies.The American journal on addictions · 2018Review
- Are Alcohol Anti-relapsing and Alcohol Withdrawal Drugs Useful in Cannabinoid Users?Neurotoxicity research · 2016Review
- Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.Current drug abuse reviews · 2012Review
- Reduced cannabis use after low-dose naltrexone addition to opioid detoxification.Journal of clinical psychopharmacology · 2010Article
- Agonist-antagonist combinations in opioid dependence: a translational approach.Dipendenze patologiche · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
Abstract
Although withdrawal severity and treatment completion are the initial focus of opioid detoxification, post-detoxification outcome better defines effective interventions. Very low dose naltrexone (VLNTX) in addition to methadone taper was recently associated with attenuated withdrawal intensity during detoxification. We describe the results of a seven-day follow-up evaluation of 96 subjects who completed inpatient detoxification consisting of the addition of VLNTX (0.125 or 0.250 mg per day) or placebo to methadone taper in a double blind, randomized investigation. Individuals receiving VLNTX during detoxification reported reduced withdrawal and drug use during the first 24 hours after discharge. VLNTX addition was also associated with higher rates of negative drug tests for opioids and cannabis and increased engagement in outpatient treatment after one week. Further studies are needed to test the utility of this approach in easing the transition from detoxification to various follow-up treatment modalities designed to address opioid dependence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.